# WOCKPHARMA (WOCKPHARMA) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/wockpharma

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹2,087.9
- Change: +0.75%
- As of: 2026-09-18
- 1D return: +0.67%
- 5D return: -6.06%
- 1M return: +13.96%
- Latest complete quarter: fy26_q4

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 18, 2026, Wockpharma is trading at ₹2086.1, showing a mixed technical picture across different timeframes. The daily and weekly timeframes indicate a bullish trend, with the price trading above key moving averages (EMA 20, EMA 50, SMA 20, SMA 50, SMA 200) and the Supertrend indicator on both periods. Weekly momentum appears strong, with a high ADX of 39.58 and rising EMAs. However, the monthly timeframe presents a conflicting signal, with the Supertrend indicator in a bearish state, although the price remains above its monthly EMAs and SMAs. Recent "EXTREME" severity anomalies on September 7 and 4, 2026, showed upward price movement accompanied by significantly higher volume (volume ratio of 5.07 and 5.08 respectively), suggesting notable buying interest.

The stock is currently positioned near the upper half of its recent trading range, with the nearest resistance level identified at ₹2101.1, approximately 0.72% above the current price. Key support is observed at ₹2061.3, about 1.19% below the current price. The stock exhibits moderate volatility, with an annualized volatility of 54% and a current drawdown of -7%. The presence of a "Bearish Engulfing Reversal" pattern on the weekly chart as of September 18, 2026, alongside a "Bullish Engulfing Reversal" on the monthly chart, highlights potential short-term caution amidst a longer-term bullish setup.

Key watch conditions include monitoring the price action around the ₹2101.1 resistance level. A sustained move above this level could reinforce the bullish sentiment. Conversely, a break below the ₹2061.3 support level, especially on increased volume, may signal a shift in momentum, particularly given the bearish monthly Supertrend. Investors should also observe the ongoing trend alignment between the daily, weekly, and monthly timeframes.

- Current price: ₹2086.1 as of September 18, 2026.
- Daily and weekly timeframes show bullish trends, with price above key moving averages and Supertrend.
- Monthly timeframe shows a bearish Supertrend, contrasting with daily and weekly trends.
- Nearest resistance: ₹2101.1 (0.72% above current price).
- Nearest support: ₹2061.3 (1.19% below current price).
- Watch for price action around ₹2101.1 resistance and ₹2061.3 support levels.

- Bearish Engulfing Reversal
- Bullish Engulfing Reversal
- Inside Bar
- Outside Bar

### What Changed

As of September 18, 2026, Wockhardt's stock traded at ₹2,086.1, a slight increase from its previous price of ₹2,072.3. The company's common name is Wockhardt, and it is listed on the NSE. Recent news includes an article discussing India's biotechnology and healthcare landscape, highlighting its potential for innovation and economic growth. No new filings were reported in the recent period. The technical indicators for daily and weekly trends were not available for comparison.

- On 2026-09-18, Wockhardt's stock price was ₹2,086.1.
- The stock price on the previous observation date was ₹2,072.3.
- A news article dated prior to 2026-09-18 discussed the Indian biotechnology and healthcare sector's potential.
- Wockhardt is listed on the NSE.

- Biotechnology and healthcare: where we are in India, and where we need to go

### Official Filings

Wockhardt Limited's recent disclosures highlight significant corporate actions and financial performance updates. On August 10, 2026, the company announced its unaudited financial results for the quarter ended June 30, 2026. Consolidated revenue from operations reached ₹929 crore, marking a 26% year-over-year increase. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) rose by 86% to ₹188 crore, and the company reported a profit before tax of ₹116 crore, a notable improvement from a loss of ₹109 crore in the same quarter of the previous year. This performance was partly attributed to a 112% growth in biotech operations revenue to ₹236 crore, driven by emerging markets, and the US FDA approval of Zaynich for specific infections on May 30, 2026.

Further developments include decisions made at the 27th Annual General Meeting (AGM) held on August 10, 2026. Shareholders approved a special resolution to raise up to ₹3,000 Crore through a Qualified Institutions Placement (QIP). The company also authorized material related party transactions totaling ₹2,100 Crore with its subsidiaries. Remuneration for key executives was also addressed, with a revision in Dr. Habil Khorakiwala's executive chairman remuneration capped at ₹10 Crore for the first year and ₹15 Crore thereafter. Additionally, a special window for re-lodging transfer requests of shares held in physical form was announced on August 25, 2026.

A Monitoring Agency Report, reviewed by the Board and Audit Committee on August 10, 2026, confirmed that Wockhardt Limited had no deviation in the utilization of QIP proceeds as of June 30, 2026. The company utilized ₹23.63 Crores from the ₹977.79 Crores raised in November 2024, primarily for capital expenditure and R&D. While the original completion timeline was fiscal year 2026, a Board resolution extended this to the end of fiscal year 2028.

- On August 10, 2026, Wockhardt Limited reported Q1 FY27 consolidated revenue of ₹929 crore (up 26% year-over-year) and profit before tax of ₹116 crore, compared to a loss of ₹109 crore in Q1 FY26.
- The 27th AGM on August 10, 2026, approved raising up to ₹3,000 Crore via Qualified Institutions Placement.
- Shareholders at the August 10, 2026 AGM authorized material related party transactions totaling ₹2,100 Crore with subsidiaries.
- A Monitoring Agency Report dated August 10, 2026, confirmed no deviation in the utilization of QIP proceeds as of June 30, 2026, with the completion deadline extended to the end of fiscal year 2028.
- A special window for re-lodging transfer requests of shares held in physical form opened on August 25, 2026.

- Pursuant to Regulation 30 read with Schedule III part A para A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of the newspaper advertisement published today i.e 25th August, 2026, regarding the opening of special window for re-lodgement of the transfer requests of shares held in physical form. |SUBJECT: Copy of Newspaper Publication
- Wockhardt Limited has informed the Exchange about Action(s) taken or orders passed (sub-para 20) |SUBJECT: Actions initiated/taken or orders passed-XBRL
- Disclosures relating to the 27th Annual General Meeting of Wockhardt Limited held on 10th August, 2026: A) Proceedings of the 27th AGM B) Scrutinizers Report on Voting Results of 27th AGM and C) Voting Results of 27th AGM. |SUBJECT: Shareholders meeting
- Pursuant to Regulation 30 of the Listing Regulations, please find enclosed Press Release on theUnaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2026. |SUBJECT: Press Release
- Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations ); and in continuation to our letter bearing reference no: WOCK/SEC/SE/2026-27/027 dated 4th August, 2026, we wish to inform you that the Board of Directors of the Company, at its meeting held today i.e. 10th August, 2026, inter-alia, has approved the Un-Audited Financial Results (Standalone & Consolidated) for the quarter ended 30th June, 2026; |SUBJECT: Outcome of Board Meeting
- Pursuant to Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Regulation 173A of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, please find enclosed Monitoring Agency Report towards utilization of proceeds of Qualified Institutions Placement ( QIP ) for the quarter ended June 30, 2026, issued by CRISIL Ratings Limited, duly reviewed and taken on record by the Board of Directors & Audit Committee of the Company. |SUBJECT: Monitoring Agency Report

### Fundamentals

Wockhardt, listed on the NSE, reported a sequential increase in Revenue from Operations for the three quarters ending in FY2025-26. Revenue grew from ₹782 crore in Q2 FY2025-26 to ₹888 crore in Q3 FY2025-26, and further to ₹965 crore in Q4 FY2025-26. Profit Before Exceptional Items And Tax also showed an upward trend sequentially, rising from ₹91 crore in Q2 FY2025-26 to ₹167 crore in Q4 FY2025-26, despite a dip to ₹77 crore in Q3 FY2025-26. Profit Before Tax followed a similar pattern, increasing from ₹91 crore in Q2 FY2025-26 to ₹189 crore in Q4 FY2025-26, with a lower figure of ₹67 crore in Q3 FY2025-26. The company's Profit Loss For Period From Continuing Operations mirrored this trajectory, moving from ₹82 crore in Q2 FY2025-26 to ₹164 crore in Q4 FY2025-26, with an interim ₹61 crore in Q3 FY2025-26. Finance costs remained relatively stable, ranging between ₹50 crore and ₹60 crore across these periods. Tax expenses fluctuated, from ₹9 crore in Q2 FY2025-26 to ₹25 crore in Q4 FY2025-26.

Key areas to monitor include the sustainability of revenue growth and the translation of this growth into consistent profitability. The fluctuations in Profit Before Exceptional Items And Tax and Profit Before Tax across the reported quarters warrant attention, particularly the dip in Q3 FY2025-26. Understanding the drivers behind these variations and the impact of tax expenses on the final profit will be important for assessing the company's operating performance.

- Revenue From Operations increased sequentially from ₹782 crore in Q2 FY2025-26 to ₹965 crore in Q4 FY2025-26.
- Profit Before Exceptional Items And Tax showed sequential growth from ₹91 crore in Q2 FY2025-26 to ₹167 crore in Q4 FY2025-26, with a dip to ₹77 crore in Q3 FY2025-26.
- Profit Loss For Period From Continuing Operations rose from ₹82 crore in Q2 FY2025-26 to ₹164 crore in Q4 FY2025-26, with an interim ₹61 crore in Q3 FY2025-26.
- Finance Costs remained between ₹50 crore and ₹60 crore across the reported quarters.
- Tax Expense varied, recorded at ₹9 crore in Q2 FY2025-26 and ₹25 crore in Q4 FY2025-26.

### Bull Case

The company's stock is exhibiting strength across multiple technical timeframes, suggesting positive momentum. On a daily basis, the closing price of ₹2086.1 is above key moving averages, including the 20-day EMA (₹2046.85) and 50-day SMA (₹1952.23). The Super Trend indicator is also showing a bullish signal. This trend extends to the weekly timeframe, where the closing price is above the 20-day EMA (₹1886.55) and 50-day SMA (₹1571.44), with a bullish Super Trend direction. The stock has also delivered significant returns over various periods, including a 37% return over the past year and a 47% year-to-date return, indicating strong performance.

- Daily closing price of ₹2086.1 is above the 20-day EMA of ₹2046.85 and 50-day SMA of ₹1952.23.
- Daily Super Trend indicator is 'bullish'.
- Weekly closing price is above the 20-day EMA of ₹1886.55 and 50-day SMA of ₹1571.44.
- Weekly Super Trend indicator is 'bullish'.
- Year-to-date return stands at 47% as of 2026-09-18.

- Biotechnology and healthcare: where we are in India, and where we need to go

### Bear Case

The company's monthly trend indicators suggest a cautionary outlook, with the Supertrend indicator at 2122.82 pointing to a bearish direction. While daily and weekly trends show bullish signals, the monthly timeframe, which reflects a longer-term perspective, indicates potential headwinds. The stock is trading near several resistance levels, with the nearest at ₹2101.1, just 0.72% above the current price of ₹2086.1. Additionally, the company has experienced a current drawdown of -7%, and its maximum drawdown historically stands at -40%, indicating periods of significant price depreciation.

- The monthly Supertrend indicator is bearish at 2122.82 as of 2026-09-18.
- The stock is trading 0.72% below the nearest resistance level of ₹2101.1.
- The current drawdown is -7%, with a historical maximum drawdown of -40%.

- Biotechnology and healthcare: where we are in India, and where we need to go

### FAQs

**What were Wockhardt's recent financial results and key operational updates?**

On August 10, 2026, Wockhardt Limited announced its unaudited financial results for the quarter ended June 30, 2026. Consolidated revenue from operations was ₹929 crore, an increase of 26% year-over-year. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) were ₹188 crore, up 86% from the previous year. The company reported a profit before tax of ₹116 crore, a significant improvement from a loss of ₹109 crore in the same quarter of the prior year. Operationally, Wockhardt highlighted the US FDA approval of its drug Zaynich for cUTI and pyelonephritis on May 30, 2026, and the European Medicines Agency's acceptance of the dossier for review. Biotech operations revenue grew 112% to ₹236 crore, driven by emerging markets.

**What key decisions were made at Wockhardt's 27th Annual General Meeting (AGM)?**

At the 27th AGM held on August 10, 2026, Wockhardt Limited's shareholders approved a special resolution to raise up to ₹3,000 Crore through a Qualified Institutions Placement. The AGM also authorized material related-party transactions totaling ₹2,100 Crore with subsidiaries Wockhardt Bio AG, CP Pharmaceuticals Limited, and Wockhardt UK Limited. Additionally, shareholders approved revisions to the remuneration of Dr. Habil Khorakiwala, capping it at ₹10 Crore per annum for the first year (March 2027–February 2028) and ₹15 Crore thereafter.

**What is the current technical trend and key price levels for Wockhardt shares?**

As of September 18, 2026, Wockhardt's daily technical trend is indicated as bullish, with the closing price at ₹2086.1. The 20-day Exponential Moving Average (EMA) is ₹2046.85 and the 50-day Simple Moving Average (SMA) is ₹1952.23. Key support levels are identified around ₹2061.3 and ₹2032.5, while resistance levels are noted near ₹2101.1 and ₹2120.0. The monthly trend, however, is indicated as bearish, with the Supertrend indicator at ₹2122.82.

**How has Wockhardt's stock performed over different periods?**

Wockhardt's stock has shown varied performance across different timeframes. Year-to-date (YTD) returns stand at 47%. Over the past year, the stock has returned 37%. More recently, it has seen a 12% return in the last month and a 72% return in the last six months. However, the return over the last five years is -6%.

- Biotechnology and healthcare: where we are in India, and where we need to go
- Pursuant to Regulation 30 read with Schedule III part A para A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of the newspaper advertisement published today i.e 25th August, 2026, regarding the opening of special window for re-lodgement of the transfer requests of shares held in physical form. |SUBJECT: Copy of Newspaper Publication
- Wockhardt Limited has informed the Exchange about Action(s) taken or orders passed (sub-para 20) |SUBJECT: Actions initiated/taken or orders passed-XBRL
- Disclosures relating to the 27th Annual General Meeting of Wockhardt Limited held on 10th August, 2026: A) Proceedings of the 27th AGM B) Scrutinizers Report on Voting Results of 27th AGM and C) Voting Results of 27th AGM. |SUBJECT: Shareholders meeting
- Pursuant to Regulation 30 of the Listing Regulations, please find enclosed Press Release on theUnaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2026. |SUBJECT: Press Release
- Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations ); and in continuation to our letter bearing reference no: WOCK/SEC/SE/2026-27/027 dated 4th August, 2026, we wish to inform you that the Board of Directors of the Company, at its meeting held today i.e. 10th August, 2026, inter-alia, has approved the Un-Audited Financial Results (Standalone & Consolidated) for the quarter ended 30th June, 2026; |SUBJECT: Outcome of Board Meeting
## Technical analytics

- As of: 2026-09-18
- Daily trend: Strong Uptrend
- Weekly trend: Moderate Uptrend
- Pivot point: ₹2,061.3
- Risk regime: Price Risk Requires Attention

### Support levels
- 1818.625
- 1645.2
- 1466.525

### Resistance levels
- 2120
- 2272.9
- 2422.3

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +0.67% |
| return_10 | +6.95% |
| return_1m | +12.16% |
| return_1y | +36.66% |
| return_20 | +13.96% |
| return_3m | +4.87% |
| return_5 | -6.06% |
| return_6m | +71.61% |
| return_since_start | +43.31% |
| return_ytd | +46.61% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | elevated_risk |
| label | Price risk requires attention |
| summary | Recent drawdown or price variability is high enough to warrant closer monitoring. |
| maximum_drawdown | -39.91% |
| annualized_volatility | +53.84% |

## Quarterly financials

- Latest complete quarter: fy26_q4

# Revenue and Profit Turn Positive for the Quarter

Wockhardt’s revenue climbed to ₹965 crore in the final quarter of FY2025‑26, a 30% increase from the same quarter a year ago. Profit before tax swung from a loss of ₹22 crore to a profit of ₹189 crore, and net profit reached ₹164 crore. Basic earnings per share rose to ₹10.23, compared with ₹3.61 in the previous quarter and a loss of ₹1.57 a year earlier.

## Revenue Growth

Revenue from operations over the last five quarters has been:

| Quarter              | Revenue (₹ crore) |
|----------------------|-------------------|
| Q4 FY2024‑25         | 743               |
| Q1 FY2025‑26         | 738               |
| Q2 FY2025‑26         | 782               |
| Q3 FY2025‑26         | 888               |
| Q4 FY2025‑26         | 965               |

After a small dip in Q1, revenue increased in each of the following three quarters. The 30% year-on-year rise in Q4 compares with a sequential increase of 8.7% from Q3.

## Profitability and Exceptional Items

Profit before exceptional items and tax improved from a loss of ₹22 crore a year earlier to a profit of ₹167 crore in Q4. After adding exceptional items, profit before tax stood at ₹189 crore. In the prior quarter, profit before exceptional items and tax was ₹77 crore and profit before tax was ₹67 crore, meaning exceptional items were a net charge of ₹10 crore. In Q4, exceptional items contributed a net gain of ₹22 crore. Even without those items, the underlying profitability showed substantial improvement.

## Tax Expense

Tax expense for the quarter was ₹25 crore, up from ₹6 crore in Q3. As a proportion of profit before tax, the tax was about 13%, compared with around 9% in Q3. The relationship between tax and pre‑tax profit has varied across quarters.

## Earnings Per Share

Basic earnings per share from continuing and discontinued operations was ₹10.23, up from ₹3.61 in Q3 and a loss of ₹1.57 a year ago. Diluted EPS was ₹10.22, indicating no material dilution. Profit from continuing operations and total profit both equalled ₹164 crore, confirming that no discontinued operations were reported during the quarter.

## Expense and Finance Cost Overview

Key operating expenses for Q4 included:
- Cost of materials consumed: ₹177 crore
- Purchases of stock‑in‑trade: ₹156 crore
- Employee benefit expense: ₹187 crore
- Depreciation and amortisation: ₹53 crore

Finance costs were ₹50 crore, down from ₹60 crore in Q3. Other income contributed ₹45 crore. The lower finance costs partially offset the rise in operating expenses.

## Key Takeaway

Wockhardt ended FY2025‑26 with its highest quarterly revenue of the year at ₹965 crore, a 30% year‑on‑year gain. Profit before tax swung from a loss to a profit of ₹189 crore, and the underlying profit before exceptional items was ₹167 crore. These results follow three consecutive quarters of revenue growth after a small decline at the start of the fiscal year.

### Ratios

## Official filings

- 2026-08-25 — Generic Announcement: Wockhardt Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_25082026164336_Relodgementoftransfernoticesigned.pdf)
- 2026-08-25 — Generic Announcement: Wockhardt Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/AIATOP_1863_WebXMLFile_20260825_185530371.xml)
- 2026-08-10 — Management Change: Wockhardt Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_10082026193556_AGMfilingCombinedsigned.pdf)
- 2026-08-10 — Press Release: Wockhardt Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_10082026164749_CombinePressPresssigned.pdf)
- 2026-08-10 — Generic Announcement: Wockhardt Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_10082026151949_OutcomeBM10082026dsigned.pdf)
- 2026-08-10 — Credit Rating Update: Wockhardt Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_10082026183757_Combine_MA_Report_Signed.pdf)
- 2026-08-07 — Generic Announcement: Wockhardt Limited has published an addendum to the notice of its 27th Annual General Meeting in Business Standard and Lokmat newspapers on August 7, 2026. The company will also place these newspaper extracts on its website. — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_07082026152835_newspaperintimation2026.pdf)
- 2026-08-05 — Official Filing: Wockhardt Limited revised the time of its 27th Annual General Meeting (AGM) from 3:30 p.m. to 10:30 a.m. IST on August 10, 2026, to be held via VC/OAVM. The company also reported related party transactions totaling INR 16,500,000,000 across various domains, including intellectual property and goods/services with subsidiaries Wockhardt Bio AG, CP Pharmaceuticals Limited, and Wockhardt UK Limited. Resolutions approved include the adoption of financial statements, re-appointment of Ms. Zahabiya Khorakiwala, ratification of cost auditor remuneration, revision of Dr. Habil Khorakiwala's remuneration to INR 150,000,000, and approval for raising up to INR 3,000 Crore via QIP.
- 2026-08-05 — Generic Announcement: Wockhardt Limited issued an addendum to the notice of its 27th Annual General Meeting (AGM), scheduled for August 10, 2026. The AGM's start time has been revised from 3:30 p.m. IST to 10:30 a.m. IST. The addendum also includes a statement regarding information provided to the Audit Committee for related party transactions, confirming that the Managing Director and CFO certified these transactions are in the company's interest. — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_05082026205000_AddendumtoNoticeSEFinal.pdf)
- 2026-08-04 — Official Filing: Wockhardt Limited will hold a board meeting on August 10, 2026, to consider its unaudited quarterly financial results for the period ended June 2026. The trading window for the company's securities will be closed from July 1, 2026, to August 12, 2026.
- 2026-07-18 — Generic Announcement: Wockhardt Limited announced its 27th Annual General Meeting will be held on August 10, 2026, via Video Conferencing. The company also confirmed the dispatch of its AGM Notice and Annual Report for FY 2026, along with details on remote and in-meeting e-voting facilities for shareholders. This information was published in the Business Standard and Lokmat newspapers on July 18, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_18072026183909_Newspaperintimationsigned.pdf)
- 2026-07-17 — Generic Announcement: Wockhardt Limited will hold its 27th Annual General Meeting on August 10, 2026, via Video Conferencing. The meeting agenda includes adopting the financial statements for FY 2025-26, appointing a director, ratifying cost auditor remuneration at ₹3,85,000 plus taxes, revising the Executive Chairman's remuneration to a maximum of ₹10 Crore per annum for the first year and ₹15 Crore thereafter, approving related party transactions up to ₹1,000 Crore with Wockhardt Bio AG and ₹550 Crore each with CP Pharmaceuticals Limited and Wockhardt UK Limited, and authorizing the raising of up to ₹3,000 Crore through various capital offerings including QIP. Additionally, Ms. Zahabiya Khorakiwala's appointment as Executive Co-chairperson of Wockhardt Bio AG with remuneration of USD 250,000 per annum is proposed, and the redeployment of approximately ₹162.33 Crore in unutilized QIP proceeds is also on the agenda. — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_17072026202419_NoticeARfinalsigned.pdf)
- 2026-07-10 — Generic Announcement: Wockhardt Limited received a certificate from its Registrar and Share Transfer Agent, MUFG Intime India Private Limited, confirming compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. This certificate covers the quarter ended June 30, 2026, and confirms that securities received for dematerialisation were processed and updated in the register of members within the prescribed timelines. — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_10072026152717_DPregulationsJune2026sd.pdf)
- 2026-07-03 — Generic Announcement: Wockhardt Limited has published a public notice regarding its 27th Annual General Meeting, with extracts appearing in the Business Standard and Lokmat Marathi Newspaper on July 3, 2026. The notice is also available on the company's website. — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_03072026135829_1WockNPadvSE03072026s.pdf)
- 2026-06-30 — Shareholding Disclosure: Dr. Habil Khorakiwala, Promoter of Wockhardt Limited, declared on April 6, 2026, that the promoters, promoter group, and persons acting in concert have not made any new encumbrances, directly or indirectly, beyond those disclosed for the financial year ended March 31, 2026. The declaration lists various entities and individuals holding a total of 49.09% of the company's share capital. — [Official attachment](https://nsearchives.nseindia.com/corporate/team_bbodade_12052026162734_WOCKPHARMA1.pdf)
- 2026-06-26 — Generic Announcement: Wockhardt Limited published a newspaper advertisement on June 26, 2026, regarding a special window for re-lodging share transfer requests for physical shares, open from February 5, 2026, to February 4, 2027, as per SEBI regulations. Transfers during this period will be issued in demat mode and subject to a one-year lock-in. The company is also providing contact information for its Registrar and Share Transfer Agent for queries. — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_26062026160401_Relodgementreg30signed.pdf)
- 2026-06-25 — Generic Announcement: Wockhardt Limited will close its trading window for equity shares from July 1, 2026, until 48 hours after the declaration of its unaudited financial results for the quarter ended June 30, 2026, in accordance with its internal code of conduct. — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_25062026150227_Trading_Window_Closuresign.pdf)
- 2026-06-11 — Generic Announcement: Wockhardt Limited disclosed the transcript of an investor meeting held on June 4, 2026, discussing the company's financial performance and strategic initiatives. The company reported a top line of INR 3,373 crores, EBITDA of INR 630 crores, and profitability before tax of INR 238 crores for the current year. Key strategic focuses include the US FDA-approved novel antibiotic Zaynich, a diabetes biosimilar franchise, and its core pharmaceutical business. The company plans to launch Zaynich in India and emerging markets, leveraging its R&D capabilities and aiming to eliminate price as a barrier to access. — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_11062026123303_WockhardtInvestorMeetTranscriptsigned.pdf)
- 2026-06-04 — Earnings Presentation: Wockhardt Limited has submitted an investor presentation on June 4, 2026, detailing its business performance and future outlook. The company reported FY26 income of INR 3,373 Cr., EBITDA of INR 630 Cr. with 51% YoY growth, and PBT of INR 238 Cr. The presentation highlights the US FDA approval of ZaynichTM, a novel antibiotic for gram-negative infections, and its upcoming launch in the US, India, and Europe. Wockhardt also plans to expand its biosimilar diabetes franchise and strengthen its pharmaceutical business in India and the UK. — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_04062026161252_CombineInvestorPresentationcoverlettersd.pdf)
- 2026-06-01 — Generic Announcement: Wockhardt Limited will hold an Investor Meet on June 4, 2026, at 4:00 PM IST at the NSE Exchange Plaza, BKC. The meeting will include strategic overviews of the company and its Zaynich business in the US and India, followed by a Q&A session with key management. Queries for the management can be submitted by June 3, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_01062026204213_Intimation_of_Institutional_Investor_Meeting_combined_recognizedsd.pdf)
- 2026-05-30 — Press Release: Wockhardt Limited announced on May 30, 2026, that the U.S. FDA has approved ZAYNICHTM (cefepime and zidebactam), an intravenous antibiotic for adult patients with complicated urinary tract infections. The approval was based on Phase 3 ENHANCE-1 trial results, where ZAYNICHTM showed a composite clinical cure and microbiologic response rate of 89.0% compared to 68.4% for meropenem. ZAYNICHTM also received approval from the Drugs Controller General of India on May 27, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_30052026181113_Wockhardt_Zaynich_FDA_Approval_Press_Release.pdf)
- 2026-05-28 — Press Release: On May 28, 2026, Wockhardt announced that India's drug regulator, CDSCO, granted marketing authorization for its antibiotic ZAYNICH® (Zidebactam/Cefepime). This approval is for treating complicated urinary tract infections, including pyelonephritis, with concurrent Gram-negative bacteremia in adult patients. The decision is supported by the ENHANCE-1 Phase 3 study, where ZAYNICH® demonstrated statistical superiority over meropenem for clinical cure and microbiological eradication. — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_28052026091512_CoverLetterpresssreleaseCombinedsigned.pdf)
- 2026-05-21 — Credit Rating Update: On May 21, 2026, ICRA Limited upgraded Wockhardt Limited's credit ratings. The long-term fund-based term loan rating was upgraded to A- (Stable) from BBB (Positive). ICRA cited improved financial performance, strong market position in formulations in India and Europe, adequate liquidity, and strengthened financial metrics. — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_21052026142404_21052026CreditRatingsd.pdf)
- 2026-05-04 — Generic Announcement: On May 4, 2026, Wockhardt Limited's Board of Directors designated Ms. Annapurna Das (President, India Business & Emerging Markets), Mr. Om Narayan (Senior Vice President, Biotech Research Centre), and Mr. Sunil Soni (Senior Vice President, Biotechnology) as Senior Management Personnel. Ms. Das has over 26 years of experience in pharmaceuticals, Mr. Narayan brings nearly three decades of experience in R&D and manufacturing, and Mr. Soni has nearly three decades of experience in API and Biotech industries. — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_04052026182343_change_in_Management.pdf)
- 2026-05-04 — Generic Announcement: Wockhardt Limited confirms no deviation in the utilization of Qualified Institutions Placement (QIP) proceeds for the quarter ended March 31, 2026, as reported by Crisil Ratings Limited. The company's Board of Directors and Audit Committee have reviewed and accepted the monitoring agency report. The utilization of net proceeds, totaling Rs 977.79 crores from the QIP initiated on November 11, 2024, aligns with the objects stated in the placement document. — [Official attachment](https://nsearchives.nseindia.com/corporate/WOCKPHARMA_04052026183027_QIP_2_MA_report_Wockhardt_Mar_26_combined.pdf)

## News and market events

- 2026-09-17 — The Hindu: **Biotechnology and healthcare: where we are in India, and where we need to go** — Explore India's biotechnology landscape and its potential to revolutionize healthcare, enhancing access, innovation, and economic growth for the future. — [Source](https://www.thehindu.com/sci-tech/health/biotechnology-and-healthcare-where-we-are-in-india-and-where-we-need-to-go/article71471597.ece)
- 2026-09-09 — Economic Times: **French food giant Danone eyes India growth without 'burning its wings'** — Danone aims for India to be a significant long-term growth engine.CEO Antoine de Saint-Affrique emphasizes profitable expansion, avoiding rapid market entry.The company focuses on specialized nutrition, building its Aptamil brand's credibility.India's demographics and growing demand for premium baby-care products are key.Danone is intentionally investing to build a sizable business from a small base. — [Source](https://economictimes.indiatimes.com/industry/services/retail/french-food-giant-danone-eyes-india-growth-without-burning-its-wings/articleshow/133982342.cms)
- 2026-09-08 — BUSINESS: **Wockhardt Ltd up for five straight sessions** — Wockhardt Ltd is quoting at Rs 2214, up 0.27% on the day as on 12:44 IST on the NSE. The stock is up 48.22% in last one year as compared to a 4.86% gain in NIFTY and a 21.83% gain in the Nifty Pharma. — [Source](https://www.business-standard.com/markets/capital-market-news/wockhardt-ltd-up-for-five-straight-sessions-126090800533_1.html)
- 2026-09-07 — CNBC-TV18: **Wockhardt shares rise 7%, extend gains for fourth consecutive session** — The Wockhardt stock has gained for seven of the previous 10 trading sessions. The company's shares were also the biggest gainer on the Nifty Pharma index in intraday trade on Monday. — [Source](https://www.cnbctv18.com/market/wockhardt-share-price-rise-fourth-straight-session-gain-top-nifty-pharma-gainer-19985466.htm)
- 2026-09-07 — Economic Times: **Wockhardt Share Price Today, Wockhardt Stock Price Live NSE/BSE Updates | The Economic Times** — Wockhardt Share Price Today - Get live NSE/BSE quotes of Wockhardt with latest news, headlines and quick analysis. View forecasts, quarterly results, dividend details, balance sheet & more. — [Source](https://economictimes.indiatimes.com/wockhardt-ltd/stocks/companyid-3731.cms)
- 2026-09-07 — MONEYCONTROL: **Trade Spotlight: How should you trade IFCI, Balaji Amines, ACME Solar Holdings, Indraprastha Gas, Tata Communications, and others on September 7?** — Trade Spotlight — [Source](https://www.moneycontrol.com/news/business/markets/trade-spotlight-how-should-you-trade-ifci-balaji-amines-acme-solar-holdings-indraprastha-gas-tata-communications-and-others-on-september-7-14023879.html)
- 2026-09-06 — Economic Times: **Ahead of Market: 10 things that will decide stock market action on Monday** — Indian benchmark indices ended slightly higher on Friday, with the Sensex rising 363 points and Nifty closing below 23,898. Investors monitored global market cues, US economic data, and inflation reports, while stock-specific action drove intraday activity across major sectors in a sideways-moving market environment. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/ahead-of-market-10-things-that-will-decide-stock-market-action-on-monday/articleshow/133834844.cms)
- 2026-08-11 — The Hindu: **Q1 Results Today Live:  Siemens, Zydus Lifesciences, MRF, RVNL, PI Industries, Manappuram Finance, NBCC, Kalpataru, Swan Defence, Bata, Gujarat Energy, KPI Green to announce Q1 results, Vi, Bosch, Zee, Bharat Forge, Hindustan Copper, Info Edge in focus** — Q1 Results Today, 11th August 2026 Live Updates:  Follow Q1FY27 live updates from businessline — [Source](https://www.thehindubusinessline.com/markets/q1-results-today-live-updates-siemens-zydus-lifescience-mrf-rvnl-pi-industries-manappuram-finance-nbcc-kalpataru-swan-defence-bata-gujarat-energy-kpi-green-vi-bosch-zee-results-11-august-2026/article71327946.ece)
- 2026-08-10 — Economic Times: **Independence Day 2026: India, which once couldn't make smallpox vaccine, has now crossed a pharma milestone the world can't ignore** — 2026 Independence Day: India's pharmaceutical industry marks a historic milestone with a new drug approval. This achievement reflects decades of growth from importing medicines to global leadership. The nation now supplies a significant portion of the world's generic medicines and vaccines. The Covid-19 pandemic further showcased the industry's manufacturing capabilities globally. Government initiatives now aim to foster innovation and high-value biopharmaceutical production. — [Source](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/independence-day-2026-india-pharma-journey-covaxin-made-in-india-drug-discovery-zaynich-wockhardt-ipa-indian-medicine-vaccine/articleshow/133003617.cms)
- 2026-08-10 — MONEYCONTROL: **Wockhardt Ltd posts Q1 PAT of Rs 107 crore** — Wockhardt Q1 results, Wockhardt q1 net profit — [Source](https://www.moneycontrol.com/news/business/earnings/wockhardt-ltd-posts-q1-pat-of-rs-107-crore-14000558.html)
- 2026-08-10 — CNBC-TV18: **Wockhardt swings to ₹106 crore profit in Q1 on 26% revenue growth** — Shares of Wockhardt Ltd ended at ₹1,932.60, down by ₹88.10, or 4.36%, on the BSE. — [Source](https://www.cnbctv18.com/market/stocks/wockhardt-share-price-swings-to-rs-106-crore-profit-in-q1-on-26-revenue-growth-19965713.htm)
- 2026-08-10 — CNBC-TV18: **Sensex Today | Stock Market LIVE Updates: Bharat Forge extends losses to 8%; Nifty below 24,550** — Sensex Today | Stock Market LIVE Updates: We are at the halfway mark of the first day of trade, and the markets are trading in a volatile space, as the Nifty index remains cautious. The index is looking to hold onto the 24,500 mark. The Nifty Bank is also under pressure, down 100 points. SBI, Adani Ports and HDFC Life are the top laggards. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-oil-banks-midcaps-bajaj-fin-pfc-kaynes-ola-bharat-forge-share-price-liveblog-19965161.htm)
- 2026-08-10 — CNBC-TV18: **Q1 Results LIVE Updates: Titan, Ola Electric react to earnings; Bharat Forge, Vodafone Idea report today** — Q1 Results LIVE Updates: Bharat Forge Vodafone Idea, Hindustan Copper, Wockhardt, Info Edge, Zee Entertainment, Linde India, ideaForge, Gland Pharma, Bosch, Astra Micro, AstraZeneca Pharma, are among the companies reporting their earnings today. Earnings reactions will come from stocks like Kaynes Tech, PFC, Delhivery and many other stocks. Watch this space for all the LIVE results updates of the first quarter. — [Source](https://www.cnbctv18.com/market/q1-results-live-updates-today-vodafone-idea-bharat-forge-pfc-kaynes-sbi-oil-titan-wockhardt-hind-copper-delhivery-ola-share-price-liveblog-19965183.htm)
- 2026-08-04 — MONEYCONTROL: **Trade Spotlight: How should you trade Wockhardt, Rail Vikas Nigam, Siemens, IndiGo, Grasim, Action Construction Equipment, and others on August 4?** — Trade Spotlight, Buy Ideas,Top Buy Ideas,Top Picks,Stock Picks,Top Stock Picks,Share Tips,Share Market Tips,Stock Tips,Stock Market Tips,Hindustan Zinc,Wockhardt,Rail Vikas Nigam,Siemens,InterGlobe Aviation,Grasim Industries,Whirlpool of India,Action Construction Equipment,Gland Pharma,Aether Industries — [Source](https://www.moneycontrol.com/news/business/markets/trade-spotlight-how-should-you-trade-wockhardt-rail-vikas-nigam-siemens-indigo-grasim-action-construction-equipment-and-others-on-august-4-13992962.html)

## Business profile

**Strategic vision:** Pharmaceutical and biotechnology company focused on research and development.

### Business segments
- **India Branded Business:** This segment likely involves the sale of branded pharmaceutical products within the Indian market.
- **Active Pharmaceutical Ingredients (API):** Wockhardt produces and supplies Active Pharmaceutical Ingredients (APIs) to other pharmaceutical manufacturers.
- **Quality Generics:** The company offers quality generic pharmaceutical products catering to broader markets.
- **Biopharmaceuticals:** Wockhardt is involved in the production of biopharmaceutical products.
- **Nutrition Products:** The company offers a range of nutrition products.
- **Vaccines:** Wockhardt produces and sells vaccines.
- **Super Specialty Hospitals:** Wockhardt operates a chain of Super Specialty Hospitals, providing healthcare services.

### Competitive strengths
- Focus on research and development for unmet medical needs.
- Integrated business model spanning pharmaceutical manufacturing and healthcare services.
- Global distribution network across multiple key markets.

## Related stocks

- [ABBOTINDIA (Healthcare)](https://faxioms.com/stocks/abbotindia) — +5.50%
- [ACUTAAS (Healthcare)](https://faxioms.com/stocks/acutaas) — +3.86%
- [AJANTPHARM (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +1.61%
- [ALKEM (Healthcare)](https://faxioms.com/stocks/alkem) — +0.14%
- [ANTHEM (Healthcare)](https://faxioms.com/stocks/anthem) — -0.35%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/wockpharma
Markdown representation: https://faxioms.com/stocks/wockpharma?render=md